



(12) Translation of
European patent specification

(11) NO/EP 3626725 B1

NORWAY

(19) NO

(51) Int Cl.

<i>C07J 9/00 (2006.01)</i>	<i>A61P 5/38 (2006.01)</i>	<i>A61P 21/00 (2006.01)</i>
<i>A61K 31/575 (2006.01)</i>	<i>A61P 5/50 (2006.01)</i>	<i>A61P 25/00 (2006.01)</i>
<i>A61K 35/00 (2006.01)</i>	<i>A61P 9/00 (2006.01)</i>	<i>A61P 29/00 (2006.01)</i>
<i>A61P 1/00 (2006.01)</i>	<i>A61P 9/10 (2006.01)</i>	<i>A61P 31/00 (2006.01)</i>
<i>A61P 1/04 (2006.01)</i>	<i>A61P 13/12 (2006.01)</i>	<i>A61P 31/14 (2006.01)</i>
<i>A61P 1/16 (2006.01)</i>	<i>A61P 17/02 (2006.01)</i>	<i>A61P 31/18 (2006.01)</i>
<i>A61P 3/00 (2006.01)</i>	<i>A61P 19/02 (2006.01)</i>	<i>A61P 31/20 (2006.01)</i>
<i>A61P 3/04 (2006.01)</i>	<i>A61P 35/00 (2006.01)</i>	<i>C07J 31/00 (2006.01)</i>
<i>A61P 3/06 (2006.01)</i>	<i>A61P 37/02 (2006.01)</i>	<i>C07J 41/00 (2006.01)</i>
<i>A61P 3/10 (2006.01)</i>	<i>A61P 43/00 (2006.01)</i>	

Norwegian Industrial Property Office

(45)	Translation Published	2023.04.03
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.11.30
(86)	European Application Nr.	19204247.1
(86)	European Filing Date	2015.05.28
(87)	The European Application's Publication Date	2020.03.25
(30)	Priority	2014.05.29, IT, FI20140130
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
(62)	Divided application	EP3149019, 2015.05.28
(73)	Proprietor	Bar Pharmaceuticals S.r.l., Via Gramsci, 88/A, 42124 Reggio Nell'Emilia (RE), Italia
(72)	Inventor	Angela, ZAMPELLA, Via Luigia Sanfelice, 71, 80127 NAPOLI, Italia Stefano, FIORUCCI, Via Assisi, 70, 06100 PERUGIA, Italia
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge


(54)	Title	CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES
(56)	References Cited:	YUSUKE IGUCHI ET AL: "Effects of Chemical Modification of Ursodeoxycholic Acid on TGR5 Activation", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), vol. 34, no. 1, 1 January 2011 (2011-01-01), pages 1-7, XP55594216, JP ISSN: 0918-6158, DOI: 10.1248/bpb.34.1 SATO HIROYUKI ET AL: "Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 51, no. 6, 27 March 2008 (2008-03-27), pages 1831-1841, XP002520339, ISSN: 0022-2623, DOI: 10.1021/JM7015864 [retrieved on 2008-02-29] VALENTINA SEPE ET AL: "Modification on Ursodeoxycholic Acid (UDCA) Scaffold. Discovery of Bile Acid Derivatives As Selective Agonists of Cell-Surface G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 18, 7 September 2014 (2014-09-07), pages 7687-7701, XP55549277, US ISSN: 0022-2623, DOI: 10.1021/jm500889f

CARMEN FESTA ET AL: "Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 20, 23 October 2014 (2014-10-23), pages 8477-8495, XP055165458, ISSN: 0022-2623, DOI: 10.1021/jm501273r
CLAUDIO D'AMORE ET AL: "Design, Synthesis, and Biological Evaluation of Potent Dual Agonists of Nuclear and Membrane Bile Acid Receptors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 3, 13 February 2014 (2014-02-13), pages 937-954, XP055165457, ISSN: 0022-2623, DOI: 10.1021/jm401873d

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>


Patentkrav

1. En forbindelse valgt fra gruppen som består av



2. Forbindelsen ifølge krav 1, hvori forbindelsen er 6 α -etyl-7 α -hydroksy-5 β -cholan-24-olsyre.

3. En forbindelse for bruk som et medikament, nevnte forbindelse er valgt fra gruppen bestående av:



4. En forbindelse for anvendelse ifølge krav 3, hvori forbindelsen er 6 α -etyl-7 α -hydroksy-5 β -cholan-24-olsyre.

5. En forbindelse for bruk ifølge krav 3, som FXR- og/eller TGR5/GPBAR1-modulator, i forebygging og/eller behandling av gastrointestinale lidelser, leversykdommer, kardiovaskulære sykdommer, aterosklerose, metabolske sykdommer, infeksjonssykdommer, kreft, nyrelidelser, inflammatorisk lidelser og nevrologiske lidelser.

6. En farmasøytisk sammensetning omfattende en forbindelse ifølge krav 1 og minst en annen farmasøytisk ingrediens.